T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
726
PBF Energy
PBF
$8.81B
| $65.1M | 0.01% |
2,400,702
+331,404
| +16% | +$10.6M |
|
727
OSI Systems
OSIS
$3.77B
| $65.1M | 0.01% |
255,062
+10,144
| +4% | +$2.65M |
|
728
Valmont Industries
VMI
$9.5B
| $64.8M | 0.01% |
161,143
-82,562
| -34% | -$33.6M |
|
729
Denali Therapeutics
DNLI
$3.97B
| $64.7M | 0.01% |
3,915,951
-652,417
| -14% | -$11M |
|
|
SGI
730
Somnigroup International
SGI
$14B
| $64.5M | 0.01% |
722,567
+51,436
| +8% | +$4.49M |
|
|
KLAR
731
Klarna Group
KLAR
$7.82B
| $64.2M | 0.01% |
2,219,867
+937,505
| +73% | +$32.2M |
|
732
Deckers Outdoor
DECK
$12.7B
| $64.1M | 0.01% |
617,924
-45,181
| -7% | -$4.23M |
|
733
Customers Bancorp
CUBI
$2.82B
| $63.7M | 0.01% |
871,596
+844,141
| +3,075% | +$57.9M |
|
734
Casey's General Stores
CASY
$31.6B
| $63.7M | 0.01% |
115,280
-2,280
| -2% | -$1.25M |
|
735
Nasdaq
NDAQ
$54.6B
| $63.6M | 0.01% |
655,305
-3,650
| -0.6% | -$328K |
|
736
Tenaris
TS
$26.6B
| $63.4M | 0.01% |
1,649,724
-137,621
| -8% | -$5.31M |
|
737
Mercury Systems
MRCY
$6.59B
| $63.3M | 0.01% |
867,670
+1,593
| +0.2% | +$118K |
|
738
Elanco Animal Health
ELAN
$11.2B
| $63.3M | 0.01% |
2,796,753
+2,378,455
| +569% | +$51.8M |
|
739
Sibanye-Stillwater
SBSW
$7.42B
| $63M | 0.01% |
+4,422,648
| New | +$53.5M |
|
740
Dorman Products
DORM
$3.95B
| $63M | 0.01% |
511,092
-152,541
| -23% | -$20.6M |
|
741
Lumen
LUMN
$6.6B
| $62.5M | 0.01% |
8,043,124
+7,082,560
| +737% | +$58.3M |
|
742
Travel + Leisure Co
TNL
$4.58B
| $62.4M | 0.01% |
885,105
+359,186
| +68% | +$23.5M |
|
743
C.H. Robinson
CHRW
$17.5B
| $62.2M | 0.01% |
387,144
+210,717
| +119% | +$31.1M |
|
744
Strategy Inc
MSTR
$38.2B
| $61.9M | 0.01% |
407,569
-63,021
| -13% | -$14.5M |
|
745
Nurix Therapeutics
NRIX
$2.82B
| $61.6M | 0.01% |
3,248,361
+2,149,268
| +196% | +$30.9M |
|
746
Hyatt Hotels
H
$16.9B
| $61.5M | 0.01% |
383,707
+296,931
| +342% | +$45.5M |
|
747
Okta
OKTA
$26.9B
| $61.3M | 0.01% |
708,364
+27,222
| +4% | +$2.38M |
|
748
Ambarella
AMBA
$3.6B
| $61.3M | 0.01% |
864,610
+828,773
| +2,313% | +$67M |
|
749
Synchrony
SYF
$26.1B
| $61.1M | 0.01% |
732,067
-38,911
| -5% | -$2.97M |
|
750
Vita Coco
COCO
$3.77B
| $60.9M | 0.01% |
1,148,453
+686,547
| +149% | +$32.2M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.